Your browser doesn't support javascript.
loading
Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse.
Yoshimoto, Takayuki; Mizoguchi, Izuru; Katagiri, Seiichiro; Tauchi, Tetsuzo; Furusawa, Jun-Ichi; Chiba, Yukino; Mizuguchi, Junichiro; Ohyashiki, Junko H; Ohyashiki, Kazuma.
Afiliación
  • Yoshimoto T; Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan.
  • Mizoguchi I; Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan.
  • Katagiri S; Department of Hematology; Tokyo Medical University; Tokyo, Japan.
  • Tauchi T; Department of Hematology; Tokyo Medical University; Tokyo, Japan.
  • Furusawa JI; Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan.
  • Chiba Y; Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan ; Department of Immunology; Tokyo Medical University; Tokyo, Japan.
  • Mizuguchi J; Department of Immunology; Tokyo Medical University; Tokyo, Japan.
  • Ohyashiki JH; Department of Molecular Oncology; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan.
  • Ohyashiki K; Department of Hematology; Tokyo Medical University; Tokyo, Japan.
Oncoimmunology ; 3: e28861, 2014.
Article en En | MEDLINE | ID: mdl-25057448
Tyrosine kinase inhibitors have dramatically improved the treatment of chronic myeloid leukemia. Recent evidence revealed that some patients with chronic myeloid leukemia can stop imatinib without relapse after achieving a complete molecular response. This review discusses the possible predictive markers to identify these patients who can stop imatinib without relapse.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Oncoimmunology Año: 2014 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Oncoimmunology Año: 2014 Tipo del documento: Article País de afiliación: Japón